Rebrand the name, change the way we eat, and save (at least part of) the ecology: the story of copi  Rebrand the name, change the way we eat, and save (at least part of) the ecology: the story of copi Reviewed by Neil Wilkof on Friday, November 11, 2022 Rating: 5
Book review: Intellectual Property Protection for AI-Generated Creations Book review: Intellectual Property Protection for AI-Generated Creations Reviewed by Hayleigh Bosher on Friday, November 04, 2022 Rating: 5

Thursday Thingies

Time has been passing by very quickly, and it is time for another Thursday Thingies. This week, we bring to you some IPKat Team News as wel...
- Thursday, November 03, 2022
Thursday Thingies Thursday Thingies Reviewed by James Kwong on Thursday, November 03, 2022 Rating: 5
Rethinking academic conferences Rethinking academic conferences Reviewed by Hayleigh Bosher on Wednesday, November 02, 2022 Rating: 5
Copyrighting the Ogopogo Monster: The © story behind the news story Copyrighting the Ogopogo Monster: The © story behind the news story Reviewed by Neil Wilkof on Tuesday, November 01, 2022 Rating: 5
Book review: The Future of Copyright in the Age of Artificial Intelligence Book review: The Future of Copyright in the Age of Artificial Intelligence Reviewed by Hayleigh Bosher on Tuesday, November 01, 2022 Rating: 5
Easy Sanitary Solutions v Group Nivelles returns to the CJEU (case C-419/22 P) Easy Sanitary Solutions v Group Nivelles returns to the CJEU (case C-419/22 P) Reviewed by Anastasiia Kyrylenko on Sunday, October 30, 2022 Rating: 5
Book review: IPEC Practice and Procedures Book review: IPEC Practice and Procedures Reviewed by Hayleigh Bosher on Friday, October 28, 2022 Rating: 5
Do we need to rethink academic conferences? Do we need to rethink academic conferences? Reviewed by Hayleigh Bosher on Thursday, October 27, 2022 Rating: 5
Nilotinib included in the Medicines Patent Pool; New voluntary licensing agreement between the Medicines Patent Pool (MPP) and Novartis Nilotinib included in the Medicines Patent Pool; New voluntary licensing agreement between the Medicines Patent Pool (MPP) and Novartis Reviewed by Frantzeska Papadopoulou on Thursday, October 27, 2022 Rating: 5
Powered by Blogger.